117 related articles for article (PubMed ID: 21180652)
21. Molecule of the month. XOMA-052.
Drug News Perspect; 2009 Oct; 22(8):497. PubMed ID: 20016858
[No Abstract] [Full Text] [Related]
22. Evaluation of the pharmacokinetics and safety of a single oral dose of fasiglifam in subjects with normal or varying degrees of impaired renal function.
Mayer M; Nudurupati S; Peng X; Marcinak J
Drugs R D; 2014 Dec; 14(4):273-82. PubMed ID: 25374042
[TBL] [Abstract][Full Text] [Related]
23. SAR, pharmacokinetics, safety, and efficacy of glucokinase activating 2-(4-sulfonylphenyl)-N-thiazol-2-ylacetamides: discovery of PSN-GK1.
Bertram LS; Black D; Briner PH; Chatfield R; Cooke A; Fyfe MC; Murray PJ; Naud F; Nawano M; Procter MJ; Rakipovski G; Rasamison CM; Reynet C; Schofield KL; Shah VK; Spindler F; Taylor A; Turton R; Williams GM; Wong-Kai-In P; Yasuda K
J Med Chem; 2008 Jul; 51(14):4340-5. PubMed ID: 18588279
[TBL] [Abstract][Full Text] [Related]
24. In vivo pharmacokinetic study and oral glucose tolerance test of sulfoxide analogs of GPR40 agonist TAK-875.
Yan Y; Xu Q; Zhao C; Dong H; Xu W; Zhang Y
Drug Dev Res; 2020 Sep; 81(6):708-715. PubMed ID: 32359092
[TBL] [Abstract][Full Text] [Related]
25. [Discovery and development of a selective GPR40/FFAR1 agonist, fasiglifam, for treatment of type 2 diabetes mellitus].
Tsujihata Y
Nihon Yakurigaku Zasshi; 2014 Aug; 144(2):59-63. PubMed ID: 25109517
[No Abstract] [Full Text] [Related]
26. Deal watch: Metabolex and Sanofi-Aventis partner on GPCR agonists for type 2 diabetes.
Nat Rev Drug Discov; 2010 Sep; 9(9):670. PubMed ID: 20811370
[No Abstract] [Full Text] [Related]
27. Discovery of a second generation agonist of the orphan G-protein coupled receptor GPR119 with an improved profile.
Semple G; Lehmann J; Wong A; Ren A; Bruce M; Shin YJ; Sage CR; Morgan M; Chen WC; Sebring K; Chu ZL; Leonard JN; Al-Shamma H; Grottick AJ; Du F; Liang Y; Demarest K; Jones RM
Bioorg Med Chem Lett; 2012 Feb; 22(4):1750-5. PubMed ID: 22264481
[TBL] [Abstract][Full Text] [Related]
28. CLX-0901 (Calyx Therapeutics).
Barlocco D
Curr Opin Investig Drugs; 2001 May; 2(5):650-3. PubMed ID: 11569941
[TBL] [Abstract][Full Text] [Related]
29. [Advances in the study of glucokinase and small molecule glucokinase activators].
Li YQ; Feng ZQ; Song HR; Guo YS; Guo ZR
Yao Xue Xue Bao; 2006 May; 41(5):390-4. PubMed ID: 16848312
[No Abstract] [Full Text] [Related]
30. [Diabetes mellitus type 2 the status of future therapy with GPR40 agonists].
Verspohl EJ
Med Monatsschr Pharm; 2014 Jul; 37(7):275. PubMed ID: 25065175
[No Abstract] [Full Text] [Related]
31. [Thiazolidenediones, diabetes and adipogenesis].
Moreno L; Barettino D
Med Clin (Barc); 1999 Apr; 112(12):457-8. PubMed ID: 10320960
[No Abstract] [Full Text] [Related]
32. [Reducing postprandial glucose levels. Glucosidase antagonists].
Neye H
Pharm Unserer Zeit; 2002; 31(3):272-8. PubMed ID: 12071124
[No Abstract] [Full Text] [Related]
33. Molecule of the month. Exenatide.
Drug News Perspect; 2003 Nov; 16(9):621. PubMed ID: 14702143
[No Abstract] [Full Text] [Related]
34. Mitiglinide: a novel agent for the treatment of type 2 diabetes mellitus.
Phillippe HM; Wargo KA
Ann Pharmacother; 2010 Oct; 44(10):1615-23. PubMed ID: 20841518
[TBL] [Abstract][Full Text] [Related]
35. Metformin: an alternative treatment for noninsulin-dependent diabetes mellitus.
Hitt CM
Conn Med; 1995 Dec; 59(12):727-30. PubMed ID: 8821636
[No Abstract] [Full Text] [Related]
36. G protein-coupled receptors as therapeutic targets for obesity and type 2 diabetes.
Bjenning C; Al-Shamma H; Thomsen W; Leonard J; Behan D
Curr Opin Investig Drugs; 2004 Oct; 5(10):1051-62. PubMed ID: 15535426
[TBL] [Abstract][Full Text] [Related]
37. [Therapeutic renaissance. Biguanides in type-2 diabetes: metformin].
Neye H
Pharm Unserer Zeit; 2002; 31(3):264-70. PubMed ID: 12071123
[No Abstract] [Full Text] [Related]
38. Exploration of the nitrogen heterocyclic periphery around the core of the advanced FFA1 agonist fasiglifam (TAK-875).
Lukin A; Bakholdina A; Zhurilo N; Onopchenko O; Zhuravel E; Zozulya S; Gureev M; Safrygin A; Krasavin M
Arch Pharm (Weinheim); 2021 Apr; 354(4):e2000275. PubMed ID: 33270252
[TBL] [Abstract][Full Text] [Related]
39. GPR119 agonists: a promising approach for T2DM treatment? A SWOT analysis of GPR119.
Kang SU
Drug Discov Today; 2013 Dec; 18(23-24):1309-15. PubMed ID: 24060477
[TBL] [Abstract][Full Text] [Related]
40. [Adverse effects of oral hypoglycemic drugs in elderly patients].
Zakowska-Wachelko B
Pol Tyg Lek; 1990 May 7-14; 45(19-20):389-91. PubMed ID: 2255657
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
